EP0282206A1 - Arylcyclobutylalkylamin-Derivat zur Behandlung von Morbus Parkinson - Google Patents
Arylcyclobutylalkylamin-Derivat zur Behandlung von Morbus Parkinson Download PDFInfo
- Publication number
- EP0282206A1 EP0282206A1 EP88301625A EP88301625A EP0282206A1 EP 0282206 A1 EP0282206 A1 EP 0282206A1 EP 88301625 A EP88301625 A EP 88301625A EP 88301625 A EP88301625 A EP 88301625A EP 0282206 A1 EP0282206 A1 EP 0282206A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- optionally substituted
- formula
- dopamine
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Definitions
- This invention relates to the medical treatment of Parkinson's disease which is due to degenerative changes in the ganglia at the base of the cerebrum.
- a method of treating Parkinson's disease in which a therapeutically effective amount of a compound of formula I in which Ar is optionally substituted phenyl, R1 is an optionally substituted aliphatic group or a carbocyclic or heterocyclic group and R2 and R3 are H or optionally substituted alkyl groups or R2 and R3 together with the nitrogen atom to which they are attached complete a heterocyclic ring is administered in conjunction with a pharmaceutically acceptable diluent or carrier.
- the compound of formula I may be administered with a dopamine precursor such as levodopa and/or a dopa decarboxylase inhibitor such as carbidopa or benserazide
- Suitable compounds of formula I are described in British Patents 2098602, 2127819 and 2128991 and in European Patent Application 191542 and may be used in the forms of pharmaceutically acceptable salts and in the form of solvates.
- a particularly preferred compound of formula I is N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate which is described in European Patent Application 230742.
- N N -Dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate is an inhibitor of dopamine reuptake and when administered to humans gives an increase in dopamine levels in plasma. It may be used alone in the treatment of Parkinson's disease or may be used in combination with a dopamine precursor such as levodopa and/or a dopa decarboxylase inhibitor such as carbidopa or benserazide.
- a dopamine precursor such as levodopa
- a dopa decarboxylase inhibitor such as carbidopa or benserazide.
- Compounds of formula I may be administered in any of the known pharmaceutical dosage forms for example solid dosage forms such as tablets or capsules or liquid dosage forms for example those forms intended for oral or parenteral administration.
- the amount of the compound of formula I to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound of formula I to be administered will be in the range 1 to 1000 mg preferably 5 to 500 mg per day given in one or more doses.
- the amount of levodopa given will be progressively increased by the physician until an optimum response is obtained.
- the actual amount will be under the control of the physician and may be up to 8 g per day given in divided doses.
- the amount of carbidopa given will be up to 100 mg per day.
- the amount of benserazide given will be up to 200 mg per day.
- the striata were homogenised with six strokes of a ptfe pestle having a clearance of 0.35 mm (manufactured by TRI-R Homogenisers Ltd.). The homogenate was centrifuged at 1000 x g for 10 minutes at 4°C and the supernatant containing a suspension of synaptosomes was used in the dopamine uptake inhibition tests described below.
- Polythene specimen tubes containing 1.5 ml Krebs solution, 0.2 ml of a solution of N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate or distilled water as control, and 0.1 ml of the synaptosome suspension were provided with an atmosphere of 5% carbon dioxide and 95% oxygen and pre-incubated at 37°C for 5 minutes.
- a solution of 14C-dopamine hydrochloride (Amersham International) was added (0.2 ml) to give a final concentration of 0.17 ⁇ M.
- the count for each tube was registered in counts per minute (cpm) and the % inhibition of uptake (I) calculated from the formula The results obtained in three replicate experiments are set out below.
- the test compound inhibited 14C-dopamine uptake in a concentration-dependent manner. The concentration which gave 50% inhibition of uptake was then calculated and is given below as the IC50 figure for each experiment.
- the mean ( ⁇ SEM) IC50 value for inhibition of dopamine uptake by the test compound is 11 ⁇ 4.2 ⁇ M.
- An in vivo test for dopamine reuptake inhibition relies on the fact that such reuptake inhibitors can prevent the entry of dopamine-depleting agents into neurons.
- Depleting agents interfere with the neuronal storage mechanism for dopamine so dopamine leaks into the cytoplasm where it is metabolised by monoamine oxidase. Depleting agents therefore induce a large reduction in brain dopamine levels which can be measured experimentally.
- Prior treatment with a dopamine reuptake inhibitor reduces the depletion of dopamine levels caused by subsequent administration of a depleting agent such as ⁇ -methyl-m-tyrosine.
- mice Male Sprague-Dawley rats (180-220 g; Charles River) were randomly assigned to various treatment groups. Two groups were dosed orally with vehicle (distilled water) and the remaining groups were given oral doses of N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate at 3 different doses. Thirty minutes later, one vehicle treated group and all the test groups were given an i.p. injection (2 ml/kg) of the depleting agent ⁇ -methyl-m-tyrosine (25 mg/kg; Sigma Chemical Co.). The group receiving vehicle (p.o.) plus ⁇ -methyl-m-tyrosine (i.p.) served as the depleted control. The remaining vehicle treated group was injected with saline i.p. to act as the absolute control.
- HPLC high pressure liquid chromatography
- the percentage prevention (P) of depletion of brain dopamine levels by test compounds is calculated from the formula
- the test compound exhibited a dose-dependent prevention of brain dopamine depletion. From the percentage prevention values obtained at three doses an oral ED50 dose was calculated, that is, the dose to prevent depletion of brain dopamine by 50%.
- the ED50 for N , N -dimethyl-1-[1-(4-chlorophenyl)cyclo-butyl]-3-methylbutylamine hydrochloride monohydrate was calculated as 44 mg/kg (p.o.).
- mice Male CD rats (Sprague-Dawley 350-400g; Charles River) were given 10, 30 or 100 mg/kg of N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate which was dissolved in distilled water and administered orally at a rate of 5 ml/kg. Control rats were orally administered distilled water. After one hour the rats were killed by CO2 inhalation overdose, the chest cavity opened and blood immediately removed from the heart and mixed with an anticoagulant solution.
- the rat blood/anticoagulant mixture was spun at 5750 x g for 20 minutes in a Heraeus Christ minicentrifuge at room temperature. The plasma was removed and kept at room temperature for as short a time as possible before analysis in the radiolabelled dopamine uptake assay.
- the fresh plasma samples from the rat study were initially maintained at 37°C for 10-15 minutes before starting the assay. 300 ⁇ l of each plasma sample was added to six 5 ml polypropylene tubes already containing 50 ⁇ l of saline at room temperature. Four of these tubes were incubated at 37°C to assess active radiolabelled dopamine uptake. The other two tubes were immediately cooled to c.3°C and maintained at this temperature to account for pasive radiolabelled dopamine uptake.
- the amount of passive uptake of 3H-dopamine at c.3°C was subtracted from the amount of active 3H-dopamine uptake at 37°C (measured in cpm) to derive net 3H-dopamine uptake.
- the resulting value was then expressed as a percentage (X) of the net 3H-dopamine uptake recorded for control plasma.
- the latter plasma samples were obtained from distilled water-treated control rats.
- the percentage inhibition value (X) was calculated using the following formula: Mean [ ⁇ 1 standard error of the mean (SEM)] percentage inhibition was then determined for each dose.
- the percentage inhibition of dopamine uptake was determined in a similar manner to that described in (3) above.
- Plasma was obtained from different animals at various periods after oral administration of a dose of 30 mg/kg of N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate.
- the results obtained are set out below: These results show that the ability of rat plasma to inhibit the uptake of dopamine into synaptosomes from rat striata persists for a considerable period of time after dosing with drug.
- Venous blood (100 ml) was collected immediately before an oral 50 mg dose of N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate was administered to six healthy human volunteers and a further venous blood sample was taken 3 hours later.
- the plasma was separated by centrifugation at 2900 x g for 20 minutes at room temperature in a Heraeus Christ minicentrifuge and was stored at -20°C prior to analysis. The samples were thawed in a water bath at 37°C for 10-15 minutes prior to commencement of the in vitro dopamine uptake assay which was performed as described in (3) above except 14C-dopamine was used.
- the assay was performed twice on plasma from each volunteer. The results obtained are given below: The mean ( ⁇ SEM) % inhibition of 14C-dopamine uptake by plasma from the six drug-treated volunteers was 14.2 ⁇ 1.4.
- the two tracts of the nigrostriatal dopamine system are independent and are located on either side of the midline of the brain.
- 6-hydroxydopamine (6-OHDA) rats will display characteristic circling behaviour after injection of dopaminergic drugs.
- the direction of rotation is dependent on the stimulus employed.
- Drugs which inhibit dopamine reuptake can only function on the unlesioned side of the brain and induce circling towards the lesion site (known as ipsilateral circling.)
- This system of co-ordinates is a modification of the de Groot system as described by Pellegrino et al (A stereotaxic atlas of the rat brain, 2nd Edition, Plenum Press 1979).
- 6-Hydroxydopamine HBr (2 ⁇ g/ ⁇ l, as base; Sigma Chemical Co.) was injected into the left substantia nigra at 1 ⁇ l/min; a total of 8 ⁇ g was administered over a period of 4 minutes using an infusion pump (Braun 'Perfusor' ED2). After removal of the cannula the skin flaps were joined with a single everted suture and the animal allowed to recover.
- Control values were determined for all rats by observing their spontaneous circling behaviour in the arenas without prior dosing. The mean turns per minute was always less than 1.
- the rats were challenged with an intraperitoneal dose of methamphetamine (2 mg/kg) and immediately placed in the arenas. In these experiments circling behaviour was monitored during two periods, 0-1h and 4-5h after dosing. Rats giving a mean of more than 5 ipsilateral turns per minute during the first hour in response to methamphetamine were used in subsequent tests. Following selection, the rats were used in groups of 5 or more rats to test the drug under investigation. The groups were made up of rats exhibiting varying responses to methamphetamine (always >5 turns/min as stated above), the mean response of the group was always more than 10 ipsilateral turns per minute.
- N N -Dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate was administered at 30 mg/kg orally and the amount of circling observed at various time periods after dosing is set out below: These results indicate that at this dose N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate has a long lasting action as an inhibitor of dopamine reuptake.
- Inhibition of dopamine reuptake in the brain reduces the rate at which dopamine is synthesised and metabolised (the turnover rate). This can be assessed by measuring the amount of the dopamine metabolite DOPAC (dihydroxyphenylacetic acid) which accumulates in the brains of rats and mice.
- DOPAC dopamine metabolite
- the administration of probenecid blocks active transport of DOPAC out of the brain. The subsequent rise in brain DOPAC concentrations is attenuated by drugs which inhibit dopamine reuptake.
- N , N -Dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate (10 mg/kg) was administered orally to male Sprague-Dawley rats (180-250g) or male CD1 mice (25-30g) (Charles River). One group of animals was killed two hours later. An additional group was administered probenecid (200 mg/kg i.p.; Sigma Chemical Co.) 30 minutes after the drug and then killed after a further 90 minutes. The animals were killed by decapitation and brains were rapidly removed and dissected on an ice-chilled porcelain plate.
- Samples were then centrifuged at 30,000 x g (whole brain samples) or at 3,500 x g (striata) using a microfuge (Beckman) set up to take 1200 ⁇ l polypropylene tubes. Aliquots (50 ⁇ l) of the clear supernatants were then injected automatically into the chromatographic system for the separation and quantification of DOPAC.
- High pressure liquid chromatography HPLC combined with electrochemical detection (ECD) was employed to assay DOPAC.
- a mobile phase 0.1M Na2HPO4: CH3OH (84:16%) containing 0.1% octanesulphonic acid, 0.1% EDTA and 0.01% Na2S2O3
- Dupont 870 pump module at a flow-rate of 1.0 ml/min to a reverse-phase analytical column (25 x 0.4 cm) and guard column (both packed with 5 ⁇ m Spherisorb ODS 2) maintained at 45°C in a thermostatically controlled cabinet.
- N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate was illustrated by the following trial.
- the amount of dopamine in the plasma of six humans subjects who had received a single dose of 30 mg N , N -dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate per day for seven days was measured in plasma samples taken two hours after administration.
- the mean value of domamine in picograms/ml is set out below at days 1, 4 and 7.
- Eight human subjects who were given placebo tablets provides plasma samples from which the mean control dopamine levels given below were obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT88301625T ATE58059T1 (de) | 1987-02-28 | 1988-02-25 | Arylcyclobutylalkylamin-derivat zur behandlung von morbus parkinson. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8704777 | 1987-02-28 | ||
GB878704777A GB8704777D0 (en) | 1987-02-28 | 1987-02-28 | Medical treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0282206A1 true EP0282206A1 (de) | 1988-09-14 |
EP0282206B1 EP0282206B1 (de) | 1990-11-07 |
Family
ID=10613147
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88902510A Pending EP0303677A1 (de) | 1987-02-28 | 1988-02-25 | Arylcyclobutyl-derivate zur behandlung von morbus parkinson |
EP88301625A Expired - Lifetime EP0282206B1 (de) | 1987-02-28 | 1988-02-25 | Arylcyclobutylalkylamin-Derivat zur Behandlung von Morbus Parkinson |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88902510A Pending EP0303677A1 (de) | 1987-02-28 | 1988-02-25 | Arylcyclobutyl-derivate zur behandlung von morbus parkinson |
Country Status (9)
Country | Link |
---|---|
US (2) | US4816488A (de) |
EP (2) | EP0303677A1 (de) |
JP (1) | JPH0643299B2 (de) |
AT (1) | ATE58059T1 (de) |
DE (1) | DE3860960D1 (de) |
GB (1) | GB8704777D0 (de) |
GR (1) | GR3001395T3 (de) |
WO (1) | WO1988006444A1 (de) |
ZA (1) | ZA881417B (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026704A1 (en) * | 1993-05-12 | 1994-11-24 | The Boots Company Plc | 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease |
WO1998013033A1 (en) * | 1996-09-25 | 1998-04-02 | Knoll Aktiengesellschaft | Medical treatment |
AU724645B2 (en) * | 1996-09-25 | 2000-09-28 | Abbott Gmbh & Co. Kg | Use of sibutramine analogues to lower lipid levels |
US6552087B1 (en) | 1999-03-19 | 2003-04-22 | Abbott Gmbh & Co. Kg | Therapeutic agent comprising (+)-sibutramine |
US6617360B1 (en) | 1996-09-21 | 2003-09-09 | Knoll Aktiengesellschaft | Medical treatment |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8501192D0 (en) * | 1985-01-17 | 1985-02-20 | Boots Co Plc | Therapeutic agents |
GB8531071D0 (en) * | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
JP2675573B2 (ja) * | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
IE61928B1 (en) * | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
US5459164A (en) * | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
DE19518988A1 (de) * | 1995-05-29 | 1996-12-05 | Basf Ag | Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit |
GB9727131D0 (en) | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
US6476078B2 (en) | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
AU2007200334B8 (en) * | 1998-08-24 | 2010-10-21 | Sepracor, Inc. | Methods of using and compositions comprising dopamine reuptake inhibitors |
US6974838B2 (en) * | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
US6696495B2 (en) * | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
BG65170B1 (bg) * | 1999-03-17 | 2007-05-31 | Knoll Gmbh | Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето |
US6372798B1 (en) | 1999-03-19 | 2002-04-16 | Knoll Pharmaceutical Company | Treatment of hyperactivity disorders |
WO2000056308A1 (en) | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Prevention of cardiovascular disease |
US6803387B1 (en) | 1999-03-19 | 2004-10-12 | Abbott Gmbh & Co. Kg | Treatment of neuropathic pain or fibromyalgia |
US6376554B1 (en) | 1999-03-19 | 2002-04-23 | Knoll Pharmaceutical Company | Method of treating sexual dysfunction |
AU3757200A (en) | 1999-03-19 | 2000-10-09 | Knoll Gmbh | Treatment of pulmonary hypertension |
WO2000056319A1 (en) | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Treatment of orthostatic hypotension |
WO2000056311A1 (en) | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Control of metabolism |
US6376551B1 (en) | 1999-03-19 | 2002-04-23 | Knoll Pharmaceutical Company | Treatment of chronic fatigue syndrome |
GB9915617D0 (en) | 1999-07-05 | 1999-09-01 | Knoll Ag | Therapeutic agents |
US6399826B1 (en) * | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
WO2002083631A1 (en) | 2001-04-13 | 2002-10-24 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
JP2005528424A (ja) * | 2002-06-04 | 2005-09-22 | アビセナ グループ インコーポレイティッド | 脳内エネルギー代謝を調節することによって認知機能障害を治療する方法 |
US7432398B2 (en) | 2005-01-06 | 2008-10-07 | Cj Corporation | Inorganic acid salts of sibutramine |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3212682A1 (de) * | 1981-04-06 | 1982-10-21 | The Boots Co. Ltd., Nottingham | Substituierte cyclobutane, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, welche diese verbindungen enthalten |
EP0108488A1 (de) * | 1982-09-30 | 1984-05-16 | The Boots Company PLC | (1-Arylcyclobutyl)(heterocyclyl)methylamin-Derivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP0111994A1 (de) * | 1982-09-30 | 1984-06-27 | The Boots Company PLC | 1-(Aryl-cyclobutyl-)alkylamin-Derivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP0191542A1 (de) * | 1985-01-17 | 1986-08-20 | The Boots Company PLC | Arylcyclobutylalkylamine und ihre Verwendung als antidepressive Arzneimittel |
EP0230742A1 (de) * | 1985-12-17 | 1987-08-05 | The Boots Company PLC | N,N-Dimethyl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamin-Hydrochlorid, Monohydrat und pharmazeutische Zusammensetzungen, welche diese enthalten |
-
1987
- 1987-02-28 GB GB878704777A patent/GB8704777D0/en active Pending
-
1988
- 1988-02-23 US US07/159,542 patent/US4816488A/en not_active Expired - Lifetime
- 1988-02-25 JP JP63502333A patent/JPH0643299B2/ja not_active Expired - Lifetime
- 1988-02-25 AT AT88301625T patent/ATE58059T1/de not_active IP Right Cessation
- 1988-02-25 DE DE8888301625T patent/DE3860960D1/de not_active Expired - Lifetime
- 1988-02-25 WO PCT/GB1988/000129 patent/WO1988006444A1/en not_active Application Discontinuation
- 1988-02-25 EP EP88902510A patent/EP0303677A1/de active Pending
- 1988-02-25 EP EP88301625A patent/EP0282206B1/de not_active Expired - Lifetime
- 1988-02-29 ZA ZA881417A patent/ZA881417B/xx unknown
- 1988-08-18 US US07/233,358 patent/US4871774A/en not_active Expired - Lifetime
-
1991
- 1991-01-29 GR GR91400096T patent/GR3001395T3/el unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3212682A1 (de) * | 1981-04-06 | 1982-10-21 | The Boots Co. Ltd., Nottingham | Substituierte cyclobutane, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, welche diese verbindungen enthalten |
EP0108488A1 (de) * | 1982-09-30 | 1984-05-16 | The Boots Company PLC | (1-Arylcyclobutyl)(heterocyclyl)methylamin-Derivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP0111994A1 (de) * | 1982-09-30 | 1984-06-27 | The Boots Company PLC | 1-(Aryl-cyclobutyl-)alkylamin-Derivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
EP0191542A1 (de) * | 1985-01-17 | 1986-08-20 | The Boots Company PLC | Arylcyclobutylalkylamine und ihre Verwendung als antidepressive Arzneimittel |
EP0230742A1 (de) * | 1985-12-17 | 1987-08-05 | The Boots Company PLC | N,N-Dimethyl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamin-Hydrochlorid, Monohydrat und pharmazeutische Zusammensetzungen, welche diese enthalten |
Non-Patent Citations (2)
Title |
---|
Lehrbuch der Pharmakologie und Toxikologie, ed. H. BADER, 1982, Edition Medizin, pages 125-127, 208, Weinheim, DE; page 208, paragraph B.4.3. * |
The Merck Index, 10th Edition, 1983, page 1054, Merck & Co. Inc., Rahway, N.J. US; Monograph 1048. * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026704A1 (en) * | 1993-05-12 | 1994-11-24 | The Boots Company Plc | 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease |
US5652271A (en) * | 1993-05-12 | 1997-07-29 | Knoll Aktiengesellschaft | Therapeutic agents |
US6617360B1 (en) | 1996-09-21 | 2003-09-09 | Knoll Aktiengesellschaft | Medical treatment |
BG64473B1 (bg) * | 1996-09-21 | 2005-04-30 | Knoll Aktiengesellschaft | Използване на сибутраминови аналози за предотвратяване развитието на диабет |
WO1998013033A1 (en) * | 1996-09-25 | 1998-04-02 | Knoll Aktiengesellschaft | Medical treatment |
AU724645B2 (en) * | 1996-09-25 | 2000-09-28 | Abbott Gmbh & Co. Kg | Use of sibutramine analogues to lower lipid levels |
US6162831A (en) * | 1996-09-25 | 2000-12-19 | Knoll Aktiengesellschaft | Medical treatment to lower uric acid levels |
US6552087B1 (en) | 1999-03-19 | 2003-04-22 | Abbott Gmbh & Co. Kg | Therapeutic agent comprising (+)-sibutramine |
Also Published As
Publication number | Publication date |
---|---|
JPH0643299B2 (ja) | 1994-06-08 |
EP0303677A1 (de) | 1989-02-22 |
GB8704777D0 (en) | 1987-04-01 |
GR3001395T3 (en) | 1992-09-11 |
EP0282206B1 (de) | 1990-11-07 |
WO1988006444A1 (en) | 1988-09-07 |
US4871774A (en) | 1989-10-03 |
JPH01500356A (ja) | 1989-02-09 |
DE3860960D1 (de) | 1990-12-13 |
US4816488A (en) | 1989-03-28 |
ATE58059T1 (de) | 1990-11-15 |
ZA881417B (en) | 1988-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0282206B1 (de) | Arylcyclobutylalkylamin-Derivat zur Behandlung von Morbus Parkinson | |
de Montigny | Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers: preliminary findings | |
Casey et al. | γ-Acetylenic GABA in tardive dyskinesia | |
Quirion et al. | Facilitation of acetylcholine release and cognitive performance by an M (2)-muscarinic receptor antagonist in aged memory-impaired | |
Charney et al. | Desipramine-yohimbine combination treatment of refractory depression: implications for the β-adrenergic receptor hypothesis of antidepressant action | |
Ewis et al. | Effect of metformin on glutathione and magnesium in normal and streptozotocin‐induced diabetic rats | |
EP1463528B1 (de) | Selektive norepinephrin-serotonin-wiederaufnahmehemmer zur behandlung des fibromyalgie-syndroms, des chronischen müdigkeitssyndroms und von schmerzen | |
Jackson et al. | Acetaminophen: a practical pharmacologic overview. | |
US20060014837A1 (en) | Use of the (1S, 2R) enantiomer of milnacipran for the preparation of a drug | |
Rivera-Calimlim et al. | The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders: Treatment with levodopa and decarboxylase inhibitor | |
Martín et al. | Simultaneous effects of p‐chloroamphetamine, d‐fenfluramine, and reserpine on free and stored 5‐hydroxytryptamine in brain and blood | |
RU2125448C1 (ru) | Фармацевтическая композиция и способ ее получения, способ лечения нарушений, развивающихся вследствие нейродегенеративных процессов | |
Cedarbaum et al. | Effect of supplemental carbidopa on bioavailability of L-dopa | |
CA3238102A1 (en) | Treating liver disorders with an ssao inhibitor | |
JP2004105190A (ja) | 神経細胞機能を維持し、その喪失を防止し、または回復させる活性について薬物を試験する方法 | |
Westenberg et al. | Kinetics of l-5-hydroxytryptophan in healthy subjects | |
Steiger et al. | Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression | |
WO2015004470A1 (en) | Hydroxychloroquine for the treatment of cardiovascular disease | |
Albazzaz et al. | Effect of azelastine on bronchoconstriction induced by histamine and leukotriene C4 in patients with extrinsic asthma. | |
KR101176347B1 (ko) | 당뇨병 환자의 신경병 통증 치료용 약제의 제조를 위한아세틸 엘 카르니틴의 용도 | |
Hinterberger | The biochemistry of catecholamines in relation to Parkinson's disease | |
Fann et al. | Effect of antidepressant and antimanic drugs on amine uptake in man | |
Garcha et al. | Distribution and effects of intestinally administered [14C]-tyramine in cats, modified by monoamine oxidase inhibitors | |
Inwang et al. | Metabolic disposition of 2-phenylethylamine and the role of depression in methadone-dependent and detoxified patients | |
HU213112B (en) | Process for preparing antidepressive pharmaceutical preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19880305 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): ES GR |
|
XX | Miscellaneous (additional remarks) |
Free format text: VERBUNDEN MIT 88902510.2/0303677 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) DURCH ENTSCHEIDUNG VOM 10.07.89. |
|
17Q | First examination report despatched |
Effective date: 19890803 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19901107 |
|
REF | Corresponds to: |
Ref document number: 58059 Country of ref document: AT Date of ref document: 19901115 Kind code of ref document: T |
|
XX | Miscellaneous (additional remarks) |
Free format text: VERBUNDEN MIT 88902510.2/0303677 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) DURCH ENTSCHEIDUNG VOM 10.07.89. |
|
REF | Corresponds to: |
Ref document number: 3860960 Country of ref document: DE Date of ref document: 19901213 |
|
ET | Fr: translation filed | ||
ITF | It: translation for a ep patent filed |
Owner name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
ITTA | It: last paid annual fee | ||
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3001395 |
|
EPTA | Lu: last paid annual fee | ||
EAL | Se: european patent in force in sweden |
Ref document number: 88301625.5 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: SCHMAUDER & PARTNER AG PATENTANWALTSBUERO Ref country code: CH Ref legal event code: PUE Owner name: ABBOTT GMBH & CO. KG Free format text: THE BOOTS COMPANY PLC#1 THANE ROAD WEST#NOTTINGHAM/NOTTS (GB) -TRANSFER TO- ABBOTT GMBH & CO. KG#MAX-PLANCK-RING 2#65205 WIESBADEN (DE) |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20061219 Year of fee payment: 20 |
|
NLS | Nl: assignments of ep-patents |
Owner name: ABBOTT GMBH & CO. KG Effective date: 20061031 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20070105 Year of fee payment: 20 Ref country code: GB Payment date: 20070105 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20070108 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20070110 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20070205 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20070228 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20070302 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TP |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20070525 Year of fee payment: 20 |
|
BE20 | Be: patent expired |
Owner name: *ABBOTT G.M.B.H. & CO. K.G. Effective date: 20080225 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20070123 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20080225 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20070201 Year of fee payment: 20 |
|
NLV7 | Nl: ceased due to reaching the maximum lifetime of a patent |
Effective date: 20080225 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20080224 |